This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Soligenix Announces $300,000 NCI SBIR Grant Award Supporting A Phase 2 Trial Of OrBec® As A Treatment For Chronic GI GVHD

PRINCETON, N.J., Sept. 4, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the National Cancer Institute (NCI) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec® (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal (GI) manifestation of chronic Graft-versus-Host disease (GVHD).  The award will provide Soligenix with approximately $300,000 over a two-year period. 

The Phase 2 study is designed as a multicenter, open-label, pilot study enrolling patients that have received allogeneic hematopoietic cell transplantation at least 100 days earlier; have documented chronic GVHD in at least one organ outside the GI tract, and have a GI biopsy consistent with chronic GI GVHD.  The primary efficacy objective of the study is to estimate the proportion of subjects with chronic GI GVHD who achieve a complete response, partial response and overall response of GI GVHD signs and symptoms when treated with orBec® for up to 16 weeks.  The study is expected to be initiated in the first half of 2013.

"We are pleased by the continued support of NCI as a collaborator supporting our oncology focused BDP clinical programs," stated Kevin J. Horgan, MD, Senior Vice President & Chief Medical Officer of Soligenix. "We look forward to working with our clinical centers to initiate this study as soon as possible to continue development of orBec® with the aim of addressing this critical unmet medical need."

"We believe that our success in securing this type of highly competitive funding is driven by the strength of our science and development capabilities," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix.  "To date, we have been fortunate to receive over $25 million in government support across both the BioTherapeutics and Vaccine/ BioDefense segments of our business, and currently have approximately $6 million in government funding remaining. We will continue to execute on our strategy of identifying and applying for new non-dilutive funding opportunities wherever appropriate." 

About Chronic GVHD

Graft-versus-Host disease (GVHD) is a major complication of allogeneic hematopoietic cell transplantation. GVHD is an inflammatory disease initiated by T cells in the donor graft that recognize histocompatibility and other tissue antigens of the host, and is mediated by a variety of effector cells and inflammatory cytokines. GVHD presents in both acute and chronic forms. The symptoms of chronic GVHD typically present at between 100 days and three years post-transplant.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs